Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03200834

Comparison of D2 vs D3 Lymph Node Dissection for Right Colon Cancer (RICON)

Comparing different method of surgical technique D2 lymph node dissection vs D3 for right colon cancer.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Colon Cancer Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

G.V. Bondar Republican Cancer Center

Donetsk, Ukraine

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Agreement of the patient to participate in trial
  • Colon cancer (only adenocarcinoma )
  • The tumor located between the cecum and the right 1/3 of transverse colon
  • Tumors T3,Т4а,b N0-2 (II-III stages)
  • Tolerance of chemotherapy
  • ECOG 0-2

Exclusion criteria

  • Patients with distant metastases
  • Tumors T1-2 (I stage)
  • Complications of tumor (perforation and full bowel obstruction)
  • Previous radiotherapy or chemotherapy
  • Synchronous or metachronous tumors
  • Women during Pregnancy or breast feeding period

Treatment and study plan

Right Hemicolectomy with D2 lymph node dissection

Procedure

Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).

Right Hemicolectomy with D3 lymph node dissection

Procedure

Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).

Primary outcomes

  1. 5-year survival

    Time frame: Up to 5 years post-operative

    death from any cause

Secondary outcomes

  1. morbidity

    Time frame: within the first 30 days after surgery

    postoperative complications

  2. mortality

    Time frame: within the first 30 days after surgery

    death after surgery

  3. Disease free survival 5 years after initial surgery

    Time frame: Up to 5 years post-operative

    local and distant metastasis during 5 years after operation

Sponsors and collaborators

Lead sponsor

G.V. Bondar Republican Cancer Center

Other

Collaborators

  • Donetsk National Medical University
  • I.M. Sechenov First Moscow State Medical University

Registry information

Important dates

Study start
2017
Primary completion
2029
Study completion
2029
First posted
Jun 27, 2017
Registry last updated
Mar 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.